4971 results for "Psychedelics"
Weiterbildung in Psychedelika-assistierter Therapie – Erfahrungen aus der Schweiz
Die Psychotherapie – February 08, 2024
Summary
Psychedelics like MDMA, LSD, and psilocybin show promise for treating affective disorders. For safe and effective Psychedelics-assisted Therapy (PAT), specialized therapist training is paramount. Existing programs globally, and in Switzerland since 2018, highlight the need for diverse qualifications. Switzerland's health authorities grant limited medical use permits for these compounds, which are products of chemical synthesis. This emerging field, relevant to Complementary and Alternative Medicine Studies, emphasizes structured education. The increasing demand and limited supply underscore the political science challenge of expanding quality training, ensuring patient access across various healthcare needs, potentially including those in gynecology.
Abstract
Zusammenfassung Erste Studienergebnisse zeigen ein Potenzial von Psychedelika und 3,4-Methylendioxy-N-methylamphetamin (MDMA) für die Behandlung vo...
Psychiatric Residents' Perspectives on Psychedelics and Psychedelic Assisted Therapy.
Journal of psychoactive drugs – July 02, 2025
Summary
Nearly 40% of future psychiatrists consider psychedelic-assisted therapy when choosing their training. A recent survey of psychiatry residency trainees revealed significant optimism for psychedelics' therapeutic potential. Despite limited formal graduate medical education on psychedelics, many residents were influenced by these emerging treatments when selecting programs, indicating a strong desire for expanded training in this promising field.
Abstract
This study evaluated the attitudes, knowledge, and educational experiences of psychiatry residents regarding psychedelics and psychedelic-assisted ...
Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program
Neuroscience Applied – January 01, 2025
Summary
Switzerland's unique program allows 723 patients with incurable diseases access to psychedelic therapy. Around 100 physicians provided approximately 1660 treatments in 2024 using MDMA (245 patients), psilocybin (348 patients), or LSD (130 patients). This medical approach, blending Psychology and Drug Studies, offers hope where conventional Medicine falls short, demonstrating a diverse academic application of chemical alkaloids.
Abstract
This article describes the Swiss limited access program for psychedelic/3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy. The Swiss Federa...
Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness
Journal of Psychopharmacology – January 01, 2023
Summary
Experience with the hallucinogen psilocybin uniquely predicts a stronger connection to nature, according to a reanalysis of 3817 participants. While other psychedelics like LSD were examined, only psilocybin reliably predicted nature relatedness. Even among exclusive psilocybin users, increased frequency correlated with greater nature relatedness. This finding, crucial for psychology and clinical psychology, distinguishes psilocybin from other substances, including those like MDMA explored in broader psychiatry and drug studies, suggesting specific therapeutic pathways.
Abstract
Background: Past research reports a positive relationship between experience with classic serotonergic psychedelics and nature relatedness (NR). Ho...
Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?
Clinical Pharmacology & Therapeutics – October 05, 2023
Summary
The potential of psychedelics like psilocybin and mescaline for conditions such as anxiety is compelling, driving new clinical trials in psychiatry. These hallucinogens influence neurotransmitter receptors, but it's unclear if their benefits truly synergize with psychological support from a psychotherapist. Rigorous 2x2 factorial clinical trials are crucial. These drug studies, vital for clinical psychology, will precisely evaluate the individual and combined effects of psilocybin and psychotherapy, informing future chemical synthesis of alkaloids and ensuring cost-effective, safe treatments.
Abstract
Clinical trials of psychedelics have provided support for their potential efficacy and safety. Although most combined a psychedelic with psychologi...
Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies
European Psychiatry – April 01, 2025
Summary
Psychedelics and Drug Studies reveal a remarkably low 0.002% incidence of psychedelic-induced psychosis in the general population (N=123,800). However, among individuals with schizophrenia, 3.8% (N=133) experienced long-lasting psychotic symptoms after psychedelic exposure. Furthermore, 13.1% (N=353) of those who experienced psychedelic-induced psychosis later developed schizophrenia. While the overall risk is low, these findings suggest a higher risk for individuals with pre-existing conditions, indicating careful consideration for future clinical trials exploring these substances.
Abstract
Introduction Persons with schizophrenia are currently excluded from psychedelic-assisted therapy due to concerns about psychedelic-induced acute or...
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Molecular psychiatry – March 01, 2025
Summary
Despite decades of concern, psychedelic-induced psychosis is extremely rare, occurring in only 0.002% of general population cases. Analysis of multiple studies reveals that while risks increase slightly in clinical settings (0.2-0.6%), psychedelics appear safer than previously thought. However, people with schizophrenia show higher sensitivity, with about 4% experiencing lasting psychotic symptoms after use. These findings suggest current blanket restrictions may need careful reconsideration.
Abstract
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. Howe...
The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin
OPAL (Open@LaTrobe) (La Trobe University) – July 08, 2025
Summary
A picomolar dose of psilocin in the medial prefrontal cortex (mPFC) can induce psychedelic-like behavior. Neuroscience reveals this specific neural activity, not in regions like the orbitofrontal cortex or striatum, acts as a critical regulator. Using optogenetics, activating these mPFC neurons in mice increased psychedelic-like responses, while inhibition suppressed them. This biology-driven understanding of psilocybin's chemistry and its central nervous system influence offers vital insights for enhancing therapeutic applications of psychedelics.
Abstract
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potentia...
Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.
Asian journal of psychiatry – June 26, 2025
Summary
When hallucinogens like LSD or psilocybin induce psychosis, prompt treatment is crucial. A review of cases found second-generation antipsychotics, such as Risperidone, highly effective in resolving psychosis. These performed significantly better than first-generation antipsychotics like Haloperidol, offering positive outcomes for patients experiencing this challenging condition.
Abstract
Psychedelics are increasingly used in the general population, yet they are associated with increased risk of psychosis in a minority of users that ...
Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice
The International Journal of Neuropsychopharmacology – May 25, 2025
Summary
Prior antidepressant use may diminish the acute effects of the hallucinogen psilocybin. Neuroscience and Pharmacology reveal that increasing serotonin levels, via classical antidepressants, dose-dependently attenuated psilocybin's 1 mg/kg acute psychedelic-like effects in mice. Conversely, depleting endogenous serotonin potentiated these effects. Biochemical Analysis and Sensing Techniques showed an inverse correlation between cortical serotonin and psilocybin’s intensity. This understanding from Psychedelics and Drug Studies, considering chemical synthesis and alkaloids, could optimize future Psychology therapies.
Abstract
Abstract Background The psychedelic psilocybin has been posited as efficacious for the treatment of depression. However, the potential link between...
Psychedelika-assistierte Psychotherapie
Die Psychotherapie – February 15, 2024
Summary
Since 2014, Switzerland has remarkably integrated psychedelics into therapy, issuing over 1000 special permits to approximately 60 psychotherapists for 2000-3000 treatments. This resurgence, a focus of modern Drug Studies, sees compounds like LSD (a product of chemical synthesis), MDMA, and psilocybin (an alkaloid) revolutionizing Psychology. These carefully structured interventions offer new avenues for mental health, building on diverse psychotherapeutic traditions. While distinct from classical Psychoanalysis, this approach emphasizes ethical standards and quality assurance, setting a compelling precedent for international practice. It broadens the scope of psychological care.
Abstract
Zusammenfassung Seit den späten 1990er-Jahren erfahren Psychedelika eine Renaissance und ziehen international vermehrt die Aufmerksamkeit auf sich....
From Adults to Adolescents: Bridging Scientific Potential and Evidence-Based Paths for Psychedelic-Assisted Interventions
Psychoactives – January 06, 2026
Summary
Psychedelic-assisted therapies show promise for treating treatment-resistant depression (TRD) in adults, yet their application to adolescents remains uncertain. Current conventional treatments often fail a significant subset of adolescents with mood disorders. This review highlights the historical context and efficacy of psychedelics, examining their potential for youth amid neurodevelopmental risks and ethical concerns. With a focus on the need for responsible assessment, it emphasizes translational gaps and research priorities necessary to explore these innovative interventions safely in adolescent mental health care.
Abstract
Adolescent mental health conditions, particularly treatment-resistant depression (TRD), represent a growing public health challenge associated with...
Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states.
Science (New York, N.Y.) – November 15, 2024
Summary
No Summary
Abstract
Psychedelics hold promise as alternate treatments for neuropsychiatric disorders. However, the neural mechanisms by which they drive adaptive behav...
Psychotherapeutisches Setting und Integration bei psychedelikaassistierter Therapie
Nervenheilkunde – April 01, 2024
Summary
Unlocking the full therapeutic potential of psychedelics in Medicine and Psychology critically depends on integrating profound experiences into daily life. While drug studies, exemplified by a clinical trial (NCT04670081) exploring psilocybin for treatment-resistant depression, advance natural compound pharmacology, the crucial integration process remains scientifically under-examined. Developing evidence-based protocols for this essential step is paramount. This will maximize the safety and long-term efficacy of these novel treatments, establishing a vital focus for diverse academic research themes in mental healthcare.
Abstract
ZUSAMMENFASSUNG Gegenstand und Ziel Der vorliegende Artikel beschäftigt sich mit der Behandlung von psychischen Erkrankungen mit psychedelischen Su...
A Perspective for Enhancing the Supervision of Psychedelic-Assisted Therapy: Motivational-Interviewing-Enhanced Integration Supervision (MIE-IS)
Psychoactives – June 25, 2025
Summary
Traditional clinical supervision often has limited impact on therapy outcomes. A novel model proposes that supervisors, by modeling Motivational Interviewing (MI) principles within supervisory relationships, can significantly enhance psychedelic-assisted therapy. This approach empowers trainees to effectively guide clients through crucial psychedelic integration, translating insights into lasting behavioral change. It fosters skill development, improves client outcomes, and promotes self-care, enhancing the overall efficacy of clinical supervision.
Abstract
While research on psychedelic-assisted therapy (PAT) continues to show promise, challenges in its clinical application persist. One relevant domain...
Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials
Journal of Psychedelic Studies – November 20, 2023
Summary
A review of nineteen informed consent forms from psychedelic clinical trials, a biomedical innovation, revealed a critical neuroethics gap. While these documents met federal inclusion criteria and regulations, they often lacked crucial information about participant vulnerability during psychedelic-assisted therapy. This oversight impacts the psychology of individuals undergoing intervention (counseling) for anxiety or treatment of major depression. Robust informed consent protocols are vital for the future of psychiatry and medicine, particularly given the unique nature of psychedelics and drug studies.
Abstract
Abstract Background and aims Psychedelic-assisted therapy (P-AT) has been shown to reduce post-traumatic stress disorder (PTSD), depression, and an...
Psychedelic-Assisted Psychotherapy
Cambridge University Press eBooks – May 28, 2021
Summary
Psychedelic-assisted psychotherapy is transforming the treatment landscape for challenging psychiatric disorders. Clinical drug studies, including those with psilocybin, show significant efficacy. Trials involving hundreds of subjects demonstrate over 60% of participants experience substantial symptom reduction, marking a major shift in psychology and psychiatry. This potent medicine, leveraging unique psychotherapy techniques, is moving from a fringe subject to a recognized method all psychotherapists should consider, with its influence on neurotransmitter receptors underpinning its therapeutic potential.
Abstract
In recent years there has been a resumption of research into the potential therapeutic benefits of psychedelic1 drugs such as MDMA2, psilocybin and...
Is MDD the right target for early-stage psychedelic-assisted therapy trials?
Journal of Psychedelic Studies – September 15, 2021
Summary
Early clinical trials suggest Major Depressive Disorder (MDD) may be an unsuitable target for initial Psychedelics and Drug Studies. The abstract argues MDD's broad definition complicates finding reliable signals for any psychological intervention, like psilocybin-assisted therapy versus escitalopram. Current psychiatric rating scales, such as QIDS, inadequately capture crucial quality of life (healthcare) aspects, vital for assessing these interventions. Moreover, the acceptance fostered by psilocybin, guided by a psychotherapist, can diverge from conventional symptom reduction goals in clinical psychology, making MDD a non-ideal focus for these randomized controlled trials.
Abstract
Abstract The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted ther...
Māori healthcare professionals' perceptions of psychedelic-assisted therapy: a qualitative study.
The New Zealand medical journal – March 14, 2025
Summary
Māori healthcare professionals show growing openness to psychedelic-assisted therapy, seeing potential alignment with traditional Indigenous healing practices. In interviews with 13 Māori health experts, participants emphasized how this innovative treatment could complement Te Ao Māori (Māori worldview) when developed with cultural sensitivity. Key findings revealed that increased understanding led to greater acceptance, with professionals supporting its potential while emphasizing the importance of equitable access and cultural safety for Māori communities.
Abstract
Psychedelic-assisted therapies are gaining interest as an innovative treatment for problems with mental health and addictions, and there are severa...
An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers
Neuroscience Applied – December 02, 2024
Summary
A single 25 mg dose of psilocybin, a compound derived from chemical synthesis and related to tryptophan, significantly reduced neuroticism in healthy volunteers for at least one month. This compelling finding in Psychology and Personality research, part of Psychedelics and Drug Studies, suggests lasting transformations. The reduction was linked to the subjective meaningfulness of the psychedelic experience and the dread of ego dissolution. Such insights into brain disorders and Clinical psychology show promise for fostering beneficial personality shifts.
Abstract
This study investigated the effects of a single high-dose of psilocybin on personality traits in psychedelic-naïve healthy volunteers. These data o...
The influence of therapists’ first-hand experience with psychedelics on psychedelic-assisted psychotherapy research and therapist training
Journal of Psychedelic Studies – October 05, 2018
Summary
As psilocybin and other psychedelics advance toward therapeutic use, a critical gap in clinical psychology persists: the undocumented influence of a psychotherapist's personal hallucinogen experience. Historical concerns previously halted empirical research. Given the unique nature of these substances—from their chemical synthesis as alkaloids to their neurotransmitter receptor influence on behavior—training for psychedelic-assisted therapy diverges from traditional psychology or drug studies. Investigating how a therapist's first-hand experience might impact a patient's sense of agency is crucial for the future of this specialized field.
Abstract
Clinical research on psychedelic-assisted psychotherapy is rapidly advancing in the USA, with two drugs, psilocybin and MDMA, progressing through a...
The association between study design and antidepressant effects in psychedelic-assisted therapy: A meta-analysis.
Journal of affective disorders – January 15, 2025
Summary
Psychedelic therapy shows varying effectiveness against depression depending on how studies are designed. A comprehensive meta-analysis reveals that psilocybin and MDMA treatments demonstrate stronger positive results in trials using non-active placebos. However, when compared to active placebos, the benefits become less pronounced. Study design choices significantly influence how effective psychedelic treatments appear to be.
Abstract
Different study designs of psychedelic trials may impact the blinding and expectance, leading to biased treatment effects. This study aimed to exam...
Structural insights into tryptamine psychedelics: The role of hydroxyl indole ring site in 5-HT2A receptor activation and psychedelic-like activity.
European journal of medicinal chemistry – January 05, 2025
Summary
The position of chemical groups on psychedelic compounds dramatically influences their effects in the brain. Scientists found that psilocin, the active form of magic mushrooms, works best when its hydroxyl group is in specific positions on its molecular structure. Using advanced simulations, they revealed how this positioning affects binding to the brain's 5-HT2A receptor, explaining why some compounds produce stronger psychedelic-like activity than others.
Abstract
Recent advancements in the study of mushroom-derived tryptamines, particularly psilocybin and its metabolite psilocin, highlight their unique psych...
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity.
The American journal of psychiatry – January 01, 2025
Summary
Psychedelics like ketamine may literally help the brain grow new connections. Scientists have identified a key protein called SV2A that could serve as a biological marker for measuring how these compounds promote neuroplasticity - the brain's ability to rewire itself. This breakthrough enables tracking of how psychedelic medicines reshape neural networks, potentially revolutionizing mental health treatment.
Abstract
Numerous preclinical studies have demonstrated that psychedelics promote the growth of cortical neurons in the prefrontal cortex. However, measurin...
Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers
Australian & New Zealand Journal of Psychiatry – July 15, 2025
Summary
Australian mental healthcare providers generally support Psilocybin and other Psychedelics for mental health, yet significant concerns persist. A survey of 109 clinicians (21% psychiatrists, 56% psychologists) revealed psychiatrists were more likely to view psychedelic use as unsafe under medical supervision and question scientific rigor compared to psychologists. While attitudes toward this emerging field of medicine are positive, particularly among those with personal experience of drug studies, gaps in evidence-based education mean many psychotherapists rely on informal sources. Targeted training is crucial for safe, effective health care.
Abstract
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and ...
Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology
Neurosurgery – December 08, 2022
Summary
Psychedelics like Psilocybin are profoundly re-emerging as potential medicine, showing promise for over a dozen neuropsychiatric conditions including severe Mood and Anxiety disorders. These hallucinogenic compounds influence brain function, acting as neuroplastogens to fundamentally alter behavior. This resurgence in drug studies highlights their potential to revolutionize Psychiatry, offering new hope for patients with complex mental health issues. Psychedelic-assisted therapy, often guided by a psychotherapist, aims to improve quality of life and brain function. This transformative approach is fostering multidisciplinary collaboration in medicine.
Abstract
After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including de...
Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy.
Front Psychol – February 05, 2025
Summary
While psychedelics show promise in mental health treatment, their effectiveness largely depends on the therapeutic context. Quality psychotherapy before, during, and after psychedelic sessions is crucial for positive outcomes. The combination of skilled therapy and carefully administered psychedelics creates a synergistic effect, helping patients process deep emotional experiences and achieve lasting psychological benefits.
Abstract
Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy.
Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia.
The Australian and New Zealand journal of psychiatry – October 01, 2024
Summary
Australians with mental health conditions show greater openness to psychedelic treatments than the general population. In a survey of 502 people, 43% supported legalizing psychedelics like MDMA and psilocybin for medical use. Those with mental illness were more likely to have tried psychedelics and view psychedelic-assisted therapy positively. Knowledge and experience strongly predicted favorable attitudes toward these treatments.
Abstract
Despite rapid advances in psychedelic sciences and the increasing number of countries legalizing psychedelics for the treatment of mental illnesses...
Are first responders interested in psychedelics? Assessing previous use, interest, and willingness to participate in psychedelic-assisted therapy
Journal of Psychedelic Studies – April 02, 2024
Summary
Many first responders face significant mental health challenges, with traditional treatments often falling short. Research explored if these frontline heroes are interested in psychedelic-assisted therapy. A survey of over 100 first responders revealed a strong positive result: high interest in exploring psychedelic-assisted therapy for their well-being. This suggests a promising new avenue for supporting first responders' mental health.
Abstract
AbstractBackground and aimsFirst responders such as firefighters and police officers often experience traumatic events as part of their work. As a ...
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
The Cochrane database of systematic reviews – September 12, 2024
Summary
Promising results show that carefully supervised psychedelic therapy may offer relief for patients facing life-threatening illnesses. Analysis of 6 clinical trials found that psilocybin and LSD sessions, combined with therapeutic support, reduced anxiety and depression symptoms in 140 participants. While side effects were generally mild and temporary, these treatments showed potential for easing emotional distress in seriously ill patients.
Abstract
Psychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians,...
Psychedelics, Psychedelic-Assisted Therapy and Employees’ Wellbeing
Journal of Management Inquiry – August 28, 2024
Summary
Breakthroughs in Psychedelics and Drug Studies highlight the potential of compounds like psilocybin and lysergic acid diethylamide for mental health. Nearly 100 companies are developing these substances, which alter perception, for psychedelic-assisted therapy involving a psychotherapist. To improve global mental health, psychology-informed research is vital to assess economic factors, employee well-being, and how to mitigate the stigma surrounding these treatments. This work aims to support successful work participation, a key determinant of mental wellness.
Abstract
There is a psychedelic renaissance with key drugs that alter perception and mood being given breakthrough therapy status as potential treatments fo...
From Isolation to Social (and Psychedelic) Integration: A Sociology of Collective Effervescence and Therapeutic Community in Psychedelic-Assisted Therapy.
Sociol Health Illn – January 01, 2025
Summary
Remarkably, feeling connected can significantly amplify healing. This work explores how psychedelic therapy, when combined with strong social bonds and shared transformative experiences, helps individuals move beyond isolation. By fostering a supportive therapeutic community, this approach promotes deep social integration. The findings underscore the profound power of human connection in achieving positive mental well-being.
Abstract
From Isolation to Social (and Psychedelic) Integration: A Sociology of Collective Effervescence and Therapeutic Community in Psychedelic-Assisted T...
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
The International journal on drug policy – January 01, 2022
Summary
While psychedelic-assisted therapy with compounds like MDMA, psilocybin, LSD (lysergic acid), ibogaine, ayahuasca, and dimethyltryptamine shows promising results for mental health, a review of National Institutes of Health (NIH) research funding from 2006-2020 found zero direct grants for clinical trials. Researchers examined NIH databases for support of these hallucinogens and other psychedelics. Despite a global "psychedelic renaissance" and other nations' governments funding such work, the NIH has not directly supported clinical trials for these innovative therapies.
Abstract
Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistent...
Psychedelic drugs and the law: What’s next?
Knowable Magazine – March 14, 2024
Summary
Over 60% of Americans support regulated therapeutic psychedelic use, driving a complex legal shift. Oregon's 2023 psilocybin service centers highlight growing state-level drug law reform, with 20 states introducing related legislation. This creates tension with federal law, where psychedelics remain Schedule I. While 5.5 million US adults use psychedelics annually, and MDMA shows promise for PTSD in Phase 3 trials, the political science of reform mirrors marijuana's path: 38 states now have medical cannabis, demonstrating states can lead significant change despite federal resistance.
Abstract
When Oregon's first psilocybin service center opened in June 2023, allowing those over 21 to take mind-altering mushrooms in a state-licensed facil...
Cultural Humility and Psychedelics: A Framework Analysis of Psychedelic-Assisted Therapy Manuals and Practice Guidelines
CrossRef – February 13, 2025
Summary
Cultural biases in healthcare lead to unequal care. An analysis of psychedelic therapy manuals, compared against established multicultural guidelines, revealed a critical gap: no manual adequately instructs therapists on delivering culturally responsive care. Bridging this gap by integrating cultural humility into training is vital for ensuring these promising new therapies benefit all individuals equitably.
Abstract
Abstract Background Cultural biases within healthcare systems result in inequitable treatment, harms, and mistrust—particularly for individuals wit...
Classifying Psychedelic-Related Complications
Current topics in behavioral neurosciences – January 01, 2026
Summary
Classic psychedelics like psilocybin and LSD show promise in treating mental health conditions, yet their rising popularity has led to increased complications. With low toxicity and minimal habit-forming potential, the risks are often underestimated by health professionals. Historical parallels with substances like opioids highlight the delayed awareness of these issues. Understanding the acute and long-term effects of psychedelics is crucial for safe therapeutic use. A nuanced classification of psychedelic-related risks can help maximize benefits while minimizing harm in both clinical and non-medical contexts.
Abstract
Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effect...
Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing.
J Psychoactive Drugs – October 30, 2024
Summary
Remarkably, positive psychedelic experiences can profoundly shift negative thought patterns. Research explored how the immediate reactions during these experiences relate to subsequent changes in negative thinking and overall wellbeing. By analyzing participants' self-reported data, it was found that positive acute reactions were strongly linked to significant reductions in negative thinking and enhanced wellbeing. This suggests these unique psychedelic experiences can foster lasting improvements in mental health.
Abstract
Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing.
A Spectrum of Selves Reinforced in Multilevel Coherence: A Contextual Behavioural Response to the Challenges of Psychedelic-Assisted Therapy Development
Frontiers in Psychiatry – December 07, 2021
Summary
The FDA's fast-tracking of two psychedelics, including psilocybin, signals a critical need for refined psychological intervention. A novel psychological flexibility model, adapting Contextual Behavioural Science, offers psychotherapists a robust framework for psychedelic-assisted therapy. This approach addresses unique challenges within the therapeutic context, integrating diverse self-perspectives into a "Spectrum of Selves." By aligning biological mechanisms with desired behavioral changes, it aims to enhance the efficacy of these compounds from drug studies, broadening treatment benefits and reducing relapse. This comprehensive behaviour therapy framework touches on cognitive psychology.
Abstract
Psychedelic-assisted therapy research for depression and PTSD has been fast tracked in the United States with the Food and Drugs Administration (FD...
Psychedelic-Assisted Psychotherapy and Mindfulness-Based Cognitive Therapy: Potential Synergies
Mindfulness – September 01, 2023
Summary
Mindfulness-Based Cognitive Therapy (MBCT) shows strong potential to enhance psychedelic-assisted psychotherapy. This integrative approach, combining systematic meditation training with cognitive therapy, targets five core processes: acceptance, presence, concentration, decentering, and embracing difficulties. MBCT's emphasis on nonjudgmental presence and cognitive restructuring can uniquely equip individuals to navigate challenging psychedelic experiences and their integration. This complementary psychological intervention may offer advantages over Acceptance and Commitment Therapy, supporting psychotherapists in optimizing outcomes in psychedelic drug studies.
Abstract
Abstract Objectives The mindfulness-informed intervention that has so far received the most attention as an adjunct to psychedelic-assisted psychot...
Perceptions of psychedelic-assisted therapy among Black Americans.
Journal of mood and anxiety disorders – December 01, 2023
Summary
No Summary
Abstract
The present study investigated differences in perceptions of psychedelic-assisted therapy between Black and White Americans, as well as factors tha...
View, meditation, action: A Tibetan framework to inform psychedelic-assisted therapy
Journal of Psychedelic Studies – March 28, 2023
Summary
Tibetan Buddhist contemplative practices offer profound insights for modern psychedelic-assisted therapy. Integrating a three-part framework—view, meditation, and action—significantly enhances therapeutic efficacy, optimizing experiences from substances like Ayahuasca. While current psychedelic and drug studies often overlook these traditions, this psychology-informed approach guides psychotherapists. It involves intensive preparatory sessions and repeated dosing for mindfulness, integrating non-ordinary experiences. Considering the chemical synthesis of alkaloids and their impact on aesthetics, plus olfactory and sensory function studies, can further refine protocols for deeper healing.
Abstract
Abstract Whether occasioned through careful, consistent meditative practice or through quicker means like the ritual ingestion of psilocybin or aya...
Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies.
JAMA psychiatry – July 01, 2023
Summary
No Summary
Abstract
Mounting evidence supports the role of spiritual, existential, religious, and theological components in mediating psychedelic-assisted therapy, yet...
Psychedelics for treating psychiatric disorders: Are they safe?
Current Psychiatry – December 01, 2022
Summary
Psychedelics are rapidly gaining prominence in Medicine, with some compounds designated "breakthrough therapies" by the FDA, expediting their development. Growing evidence from Drug Studies highlights their potential for treating psychiatric disorders like depression, PTSD, and substance use disorders, often alongside psychotherapy. While ketamine already treats depression and other Psychedelics anticipate FDA approval, understanding their safety profile is crucial. These substances, including psilocybin and MDMA, are generally well-tolerated, though associated with various adverse effects, signaling a significant shift in Psychiatry.
Abstract
SAM FALCONERP sychedelics are a class of substances known to produce alterations in consciousness and perception.In the last 2 decades, psychedelic...
The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey
Palliative & Supportive Care – November 03, 2022
Summary
Health care practitioners widely recognize the potential of psychedelic-assisted therapy as an intervention for cancer patients experiencing anxiety and distress. Professionals in Medicine and Psychiatry perceive significant benefits, especially for advanced cancer. While US health care practitioners showed greater awareness of psychedelics, those in New Zealand more strongly emphasized incorporating Indigenous and spiritual health perspectives into such drug studies. This indicates a growing openness within cancer care to novel approaches for profound distress, particularly in palliative contexts.
Abstract
Abstract Objectives A resurgence of research investigating the administration of psychedelic compounds alongside psychotherapy suggests that this t...
Changes in default-mode network activity and functional connectivity as an indicator of psychedelic-assisted psychotherapy effectiveness
Neuropsychiatria i Neuropsychologia – January 01, 2018
Summary
Profound changes in brain activity can signal the effectiveness of psychedelic-assisted psychotherapy. A Neuropsychiatry and Neuropsychology investigation with 25 participants found that a 25% decrease in the default mode network's functional connectivity correlated with positive therapeutic outcomes. This finding, central to Psychology and Psychedelics and Drug Studies, offers a vital biological marker for mental health research topics, highlighting neural patterns in treatment success.
Abstract
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Ruban A, Kołodziej A. Changes in default-mode network activity an...
The Readiness of Psychiatrists to Implement Psychedelic-Assisted Psychotherapy
Frontiers in Psychiatry – November 26, 2021
Summary
A compelling finding reveals 77.2% of 83 participating psychiatrists support controlled psychedelic use for mental health. While all were familiar with these substances, none felt prepared to deliver psychedelic-assisted psychotherapy. Thematic analysis of focus group discussions highlighted a critical need for knowledge and preparedness, despite an openness to experience within psychiatry. As psychedelic medicine moves towards mainstream mental health, psychotherapists and medical professionals require significant training to integrate these emerging treatments, which are increasingly a focus in Complementary and Alternative Medicine Studies, into practice.
Abstract
Introduction: Psychedelic-assisted psychotherapy is a promising approach in psychiatry; evidence is growing and it may not be long before mainstrea...
Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review
Psychological Medicine – January 01, 2025
Summary
Psychedelics are poised for widespread psychiatric use, making urgent ethical questions paramount. A comprehensive review across 5 databases identified 7 critical themes for these drug studies. These range from patient safety and robust therapeutic relationships to informed consent and equitable access, considering the profound neurotransmitter receptor influence on behavior. Addressing these issues is vital for responsible deployment of these powerful compounds, ensuring patient well-being and societal integration.
Abstract
Abstract Based on promising preliminary results from clinical trials, it seems likely that psychedelic substances (classic serotonergic psychedelic...
The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin
ACS Pharmacology & Translational Science – July 08, 2025
Summary
A breakthrough in **Neuroscience** reveals the **prefrontal cortex** critically regulates **psychedelic** effects. A picomolar dose of psilocin, an **alkaloid**, in the medial **prefrontal cortex** of male mice was sufficient to induce the Head Twitch Response, a key psychedelic-like behavior. This finding, crucial for **Psychedelics and Drug Studies** and **Psychology**, demonstrates how neural activity in this region drives these potent effects, influencing **Neurotransmitter Receptor Influence on Behavior**. Optogenetic manipulation further confirmed this, with activation increasing and inhibition suppressing the response. This **Neuroscience** insight promises safer therapeutic applications.
Abstract
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potentia...
Psychedelic-Assisted Group Therapy: A Systematic Review
Journal of Psychoactive Drugs – March 15, 2019
Summary
While individual psychedelic-assisted psychotherapy modalities receive much attention, a new review explores the overlooked history of group psychotherapy. Classic hallucinogens like psilocybin and lysergic acid diethylamide, substances derived from chemical synthesis and alkaloids, were often integrated into group psychotherapy. This systematic review compiles experimental methods and clinical outcomes, including participant numbers and observed effects. Understanding their influence on neurotransmitter receptors and behavior is crucial for clinical psychology and medicine. This work stimulates hypotheses for future psychedelics and drug studies, informing psychotherapist practice across various modalities.
Abstract
Contemporary research with classic psychedelic drugs (e.g., lysergic acid diethylamide (LSD) and psilocybin) is indebted to the twentieth-century r...
What motivates spiritual health practitioners in psychedelic-assisted therapy? A qualitative study and implications for facilitator training practices
Psychedelics – April 29, 2025
Summary
Intriguingly, spiritual care providers in psychedelic therapy are often driven by profound personal experiences. A qualitative investigation of 15 practitioners revealed that direct encounters with psychedelics frequently sparked their initial interest. They find deep fulfillment and personal growth by witnessing patient healing. This personal insight is invaluable, and robust facilitator training emphasizing self-reflection ensures objective, high-quality spiritual care for patient well-being.
Abstract
Spiritual health practitioners (SHPs), also known as healthcare chaplains, are increasingly involved in facilitating psychedelic-assisted therapies...
Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice
Journal of Mental Health and Addiction Nursing – February 19, 2020
Summary
Psychedelic-assisted therapy is showing unprecedented success in treating mental illness and addictions, transforming Medicine and Psychology. A review of 20 years of literature reveals that while Natural Compound Pharmacology Studies are advancing, nursing's vital role in this emerging field remains largely undefined. Nurses, as advocates for safe, ethical practice in Psychedelics and Drug Studies, are uniquely positioned to lead the development of practice, policy, and education. Their expertise is crucial for integrating these powerful treatments, derived from chemical synthesis and alkaloids, into mainstream care.
Abstract
Background Psychedelic-assisted therapy research is demonstrating unprecedented rates of success in treating mental illness, addictions, and end-of...
A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia
Australian & New Zealand Journal of Psychiatry – April 16, 2024
Summary
The Australian government's rescheduling of psilocybin for medicine creates significant regulatory challenges for psychedelic-assisted therapy. To provide clarity, a comprehensive taxonomy was developed, identifying six main regulatory domains. Three domains—Service Establishment, Practitioner, and Treatment Delivery—show substantial uncertainty, including facility location and therapist qualifications. This taxonomy offers vital context for psychology and drug studies, providing a roadmap for health services and government policymakers. It addresses practical and ethical considerations for integrating psilocybin, an alkaloid, into medicine, informing future political science and public relations efforts around drug analysis and supply.
Abstract
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change ...
How Psychedelic-Assisted Treatment Works in the Bayesian Brain
Frontiers in Psychiatry – March 08, 2022
Summary
Psychedelics are experiencing a Renaissance in clinical **Psychology**, offering promising **Psychological intervention**. Their unique synergy combines **Neurotransmitter Receptor Influence on Behavior** with **Psychotherapist** guidance. These substances, often alkaloids from **Chemical synthesis**, appear to make deeply held beliefs more revisable, a key insight from **Cognitive psychology**. This allows new input to be incorporated more readily. Psychotherapy then provides crucial input, establishing a safe environment and fostering positive expectations (the "set"). This accelerated process enhances the **remedial education** aspect of therapy, a vital frontier in **Psychedelics and Drug Studies**, leading to symptom relief.
Abstract
Psychedelics are experiencing a renaissance in clinical research. In recent years, an increasing number of studies on psychedelic-assisted treatmen...
Older adults in psychedelic-assisted therapy trials: A systematic review
Journal of Psychopharmacology – January 01, 2024
Summary
Psychedelic-assisted psychotherapy appears safe and well-tolerated for older adults, with no serious adverse events among the 10 participants for whom detailed safety data was available. This systematic review, using MEDLINE and other sources for Psychedelics and Drug Studies, analyzed 36 trials involving 1400 patients. Yet, only 19 (less than 1.4%) were aged 65 or older. While initial findings suggest these substances, often from chemical synthesis and alkaloids, modulating neurotransmitter receptors for behavioral influence, are safe, their potential in geriatric Psychology and Medicine warrants further exploration by psychotherapists.
Abstract
Background: Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid di...
Older Adults in Psychedelic-Assisted Therapy Trials: A Systematic Review
European Psychiatry – April 01, 2024
Summary
Psychedelic-assisted psychotherapy appears safe for older adults, with no serious adverse events reported in initial data. A systematic review of 36 drug studies, involving 1,400 patients, found only 19 (less than 1.4%) were 65 or older. Detailed safety data for 10 older adults reported only transient mild anxiety or hypertension during sessions. This suggests these compounds, often products of chemical synthesis or alkaloids, are well-tolerated in Medicine and Psychology, offering psychotherapists a potential path to address mental health conditions and influence well-being.
Abstract
Introduction Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, LSD, MDMA and o...
Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives.
General hospital psychiatry – July 03, 2025
Summary
The unique subjective experiences linked to psychedelics might be central to their mental health benefits. This raises a key question: are these intense "trips" necessary for healing? Research explores if non-hallucinogenic compounds can offer similar brain benefits, like neuroplasticity, without the acute subjective effects. The positive results suggest both approaches have a vital role, broadening future psychiatric treatment options.
Abstract
The resurgence of interest in classical psychedelics brings both promise and challenges to psychiatric care. Increasing evidence supports the thera...
Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations
OpenAlex – December 30, 2020
Summary
Psychedelics profoundly enhance the **feeling** of truth and **meaning** attributed to experiences, a phenomenon with significant implications for **Psychology**. While this can drive therapeutic benefits, it also presents ethical challenges regarding knowledge **mediation** and validation. As psychedelics become **mainstream** in **Drug Studies**, concerns arise about potentially reinforcing false beliefs. A framework is proposed, emphasizing **apprenticeship** practices for integrating experiences. This approach considers **social psychology** through intersubjective, historical, and cultural contexts, crucial for understanding the **epistemology** of psychedelic insights. These considerations are illustrated through **three examples**.
Abstract
A striking feature of psychedelics is their ability to increase attribution of truth and meaningfulness to specific contents and ideas experienced,...
Nursing in psychedelic-assisted psychotherapy: new opportunities and future prospects
British Journal of Mental Health Nursing – February 02, 2024
Summary
The rise of psychedelic-assisted therapy is opening up new professional avenues for nurses. Drawing on expert insights, this exploration highlights the currently undefined but crucial role nurses can play. It reveals significant opportunities for professional development as these innovative treatments gain wider acceptance, emphasizing that nursing input will be essential for successful future integration.
Abstract
This article looks at the emerging field of psychedelic-assisted psychotherapy and the nurse's role within that – something which is currently unex...
Medical student attitudes and perceptions of psychedelic-assisted therapies
Frontiers in Psychiatry – June 27, 2023
Summary
Nearly 80% of medical students (78.6%) believe psychedelics possess therapeutic potential, despite a general lack of knowledge about these agents. A survey of 132 future medical professionals in Nevada (22.7% response rate) revealed overwhelmingly positive attitudes. Using a Likert scale, students expressed curiosity about psychedelics and drug studies, with 95.2% agreeing further investigation is warranted for conditions in psychiatry. However, uncertainty persists regarding neurocognitive risks. This highlights a critical need for robust medical education on psychedelics as clinical psychology and medicine evolve.
Abstract
Introduction Although certain psychedelic agents may soon gain federal approval for use in treating specific psychiatric conditions, the utilizatio...
Psychedelic-assisted therapy for people with gambling disorder?
Journal of Behavioral Addictions – March 26, 2024
Summary
Psychedelic-assisted therapy, guided by a psychotherapist, shows exciting potential for treating gambling disorder. This severe mental health challenge, often linked to significant anxiety and depression, shares psychosocial and neurobiological underpinnings with other addictions. Drawing from promising results in clinical psychology for conditions like PTSD and substance use disorders, experts propose that carefully integrated psychedelic treatments could offer a novel approach to address problematic gambling behavior, potentially influencing brain chemistry. This innovative strategy merits exploration within psychiatry.
Abstract
Abstract Gambling disorder is a severe mental health and behavioural problem with harmful consequences, including financial, relationship and menta...